Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
Adding the lutetium-labelled PSMA*-617 (177Lu PSMA-617) targeted radioligand therapy to standard of care (SOC) led to significant extension of radiographic progression-free survival (rPFS) and overall survival (OS) compared with SOC alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after treatment with chemotherapy and androgen inhibitors, according to the VISION trial presented at ASCO 2021.
Injecting a hydrogel spacer is useful for putting some distance between the rectum and prostate during radiotherapy for prostate cancer, a study reports. As a result, radiation exposure in the rectum is minimized, and late gastrointestinal and genitourinary toxicities are reduced.
Final analysis of the phase III TITAN* trial, presented at ASCO GU 2021, has shown that the addition of apalutamide to androgen deprivation therapy (ADT) improves overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC).
New drug applications approved by US FDA as of 16 - 31 December 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.